BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21132024)

  • 1. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients.
    Norman BC; Jacobsohn DA; Williams KM; Au BK; Au MA; Lee SJ; Moravec CK; Chien JW
    Bone Marrow Transplant; 2011 Oct; 46(10):1369-73. PubMed ID: 21132024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.
    Williams KM; Cheng GS; Pusic I; Jagasia M; Burns L; Ho VT; Pidala J; Palmer J; Johnston L; Mayer S; Chien JW; Jacobsohn DA; Pavletic SZ; Martin PJ; Storer BE; Inamoto Y; Chai X; Flowers MED; Lee SJ
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):710-716. PubMed ID: 26475726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant.
    Cheng GS; Storer B; Chien JW; Jagasia M; Hubbard JJ; Burns L; Ho VT; Pidala J; Palmer J; Johnston L; Mayer S; Crothers K; Pusic I; Lee SJ; Williams KM
    Ann Am Thorac Soc; 2016 Nov; 13(11):1932-1939. PubMed ID: 27513368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effect of budesonide/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
    Kim SW; Rhee CK; Kim YJ; Lee S; Kim HJ; Lee JW
    Respir Res; 2016 May; 17(1):63. PubMed ID: 27229850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study.
    Verleden GM; Verleden SE; Vos R; De Vleeschauwer SI; Dupont LJ; Van Raemdonck DE; Vanaudenaerde BM
    Transpl Int; 2011 Jul; 24(7):651-6. PubMed ID: 21401732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventing and managing bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation.
    Chien JW
    Expert Rev Respir Med; 2011 Feb; 5(1):127-35. PubMed ID: 21348593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the therapeutic potential of the cysteinyl leukotriene antagonist Montelukast in the treatment of bronchiolitis obliterans syndrome following lung and hematopoietic-stem cell transplantation and its possible mechanisms.
    Kordjazy N; Amini S
    Ther Adv Respir Dis; 2024; 18():17534666241232284. PubMed ID: 38504551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial.
    Ruttens D; Verleden SE; Demeyer H; Van Raemdonck DE; Yserbyt J; Dupont LJ; Vanaudenaerde BM; Vos R; Verleden GM
    PLoS One; 2018; 13(4):e0193564. PubMed ID: 29624575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT--a randomized double-blinded placebo-controlled study.
    Lam DC; Lam B; Wong MK; Lu C; Au WY; Tse EW; Leung AY; Kwong YL; Liang RH; Lam WK; Ip MS; Lie AK
    Bone Marrow Transplant; 2011 Dec; 46(12):1551-6. PubMed ID: 21317934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled corticosteroids or montelukast as the preferred primary long-term treatment for pediatric asthma?
    Jartti T
    Eur J Pediatr; 2008 Jul; 167(7):731-6. PubMed ID: 18214538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azithromycin for the Treatment of Obliterative Bronchiolitis after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Yadav H; Peters SG; Keogh KA; Hogan WJ; Erwin PJ; West CP; Kennedy CC
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2264-2269. PubMed ID: 27575542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation.
    Inamoto Y; Martin PJ; Onstad LE; Cheng GS; Williams KM; Pusic I; Ho VT; Arora M; Pidala J; Flowers MED; Gooley TA; Lawler RL; Hansen JA; Lee SJ
    Transplant Cell Ther; 2021 Sep; 27(9):759.e1-759.e8. PubMed ID: 34126278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Phase II Trial of Montelukast to Treat Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation and Investigation into Bronchiolitis Obliterans Syndrome Pathogenesis.
    Williams KM; Pavletic SZ; Lee SJ; Martin PJ; Farthing DE; Hakim FT; Rose J; Manning-Geist BL; Gea-Banacloche JC; Comis LE; Cowen EW; Justus DG; Baird K; Cheng GS; Avila D; Steinberg SM; Mitchell SA; Gress RE
    Transplant Cell Ther; 2022 May; 28(5):264.e1-264.e9. PubMed ID: 35114411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to explore preventive and novel therapies for bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.
    Sengsayadeth SM; Srivastava S; Jagasia M; Savani BN
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1479-87. PubMed ID: 22449611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcineurin inhibitors in bronchiolitis obliterans syndrome following stem cell transplantation.
    Hostettler KE; Halter JP; Gerull S; Lardinois D; Savic S; Roth M; Tamm M
    Eur Respir J; 2014 Jan; 43(1):221-32. PubMed ID: 23645405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation.
    Au BK; Au MA; Chien JW
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1072-8. PubMed ID: 21126596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nintedanib in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation.
    Tang W; Yu T; Dong T; Liu T; Ji J
    Chest; 2020 Sep; 158(3):e89-e91. PubMed ID: 32892892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.
    Bergeron A; Chevret S; Granata A; Chevallier P; Vincent L; Huynh A; Tabrizi R; Labussiere-Wallet H; Bernard M; Chantepie S; Bay JO; Thiebaut-Bertrand A; Thepot S; Contentin N; Fornecker LM; Maillard N; Risso K; Berceanu A; Blaise D; Peffault de La Tour R; Chien JW; Coiteux V; Socié G;
    JAMA; 2017 Aug; 318(6):557-566. PubMed ID: 28787506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome.
    Verleden GM; Vanaudenaerde BM; Dupont LJ; Van Raemdonck DE
    Am J Respir Crit Care Med; 2006 Sep; 174(5):566-70. PubMed ID: 16741151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic role of FEV1 for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.
    Ahn JH; Jo KW; Song JW; Shim TS; Lee SW; Lee JS; Kim DY; Lee JH; Lee JH; Choi Y; Lee KH
    Clin Transplant; 2015 Dec; 29(12):1133-9. PubMed ID: 26383085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.